Novogen has unwound its CanTx JV with Yale and resumed 100% ownership of its lead superbenzopyran Cantrixil, as it prepares to enter the clinic in ovarian cancer patients in Q416. Separately, its anti-tropomyosin (ATM) drug Anisina, which shows strong synergy with standard-of-care anti-mitotic drugs, is scheduled to enter the clinic in H216 or H117 (pending successful completion of toxicology studies). With $29m cash, we believe that Novogen is funded through FY18. Our valuation is virtually
11 May 2016
Cantrixil to enter clinic in H216
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cantrixil to enter clinic in H216
Novogen has unwound its CanTx JV with Yale and resumed 100% ownership of its lead superbenzopyran Cantrixil, as it prepares to enter the clinic in ovarian cancer patients in Q416. Separately, its anti-tropomyosin (ATM) drug Anisina, which shows strong synergy with standard-of-care anti-mitotic drugs, is scheduled to enter the clinic in H216 or H117 (pending successful completion of toxicology studies). With $29m cash, we believe that Novogen is funded through FY18. Our valuation is virtually